Response to: “Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test”
Sign Up to like & getrecommendations! Published in 2020 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2020.103139
Abstract: We value all comments on our research, and the opportunity to provide further information on our study describing the HPV16-specific tumour marker DRH1 [1]. We used an assay that was CE certified under the European… read more here.
Keywords: response study; study; hpv16; test ... See more keywords